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Myasthenia gravis (MG)  I  is  an organ-specific autoimmune disease of  skeletal 
muscle. Both cellular and humoral immunity to nicotinic acetylcholine recep- 
tors (AChR) are demonstrable in patients with MG  (1).  Experimental autoim- 
mune  myasthenia  gravis  (EAMG)  can be induced in animals  by a  single 
immunization with solubilized AChR  and complete Freund's adjuvant (CFA). 
The chronic phase of  EAMG  in rats has proven an excellent animal model for 
MG  (1). EAMG  can be adoptively transferred to normal animals by living 
immune lymph node cells (2, 3) but an effector role has not been demonstrated 
for T cells in the pathogenesis of EAMG or MG. Helper T cells participate in the 
rat's  autoantibody response  to  AChR  (2,  4).  Considerable evidence indicates 
that  anti-AChR  antibodies  play  a  central  role  in  impairing  neuromuscular 
transmission both in EAMG and MG (5). 
When Bordetella pertussis is used as a  supplementary adjuvant, a transient 
acute phase of weakness occurs in Lewis rats 7-8 days after inoculation with 
AChR (6). Acute EAMG is characterized histologically by infiltration of motor 
end plates with mononuclear inflammatory cells which separate nerve termi- 
nals from the muscle's postsynaptic membrane  (7). That membrane is  selec- 
tively destroyed by intensely phagocytic cells.  Acute EAMG can be passively 
transferred to normal rats by intravenous injection of  the IgG fraction from sera 
of rats with chronic EAMG (8), Usually within 4 days of the onset of weakness, 
clinical recovery occurs and inflammatory cells disappear. 
It  is  not  known  what  preclinical  events  lead  to  simplification of muscle 
postsynaptic membranes and loss of AChR in spontaneously occurring MG (9). 
A human counterpart of acute EAMG has not yet been described but occasional 
association of polymyositis with MG  (10) and occurrence of muscle "lymphor- 
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rhages"  in  MG  may  be  evidence  of a  similar  inflammatory  cellular  event  in 
MG. 
To investigate the role of complement as a potential mediator of the pathogen- 
icity  of anti-AChR  antibodies  in  vivo,  rats  were  depleted  of complement  by 
treatment  with  cobra venom factor before  injection  of anti-AChR  antibodies. 
Other  rats  were  depleted  of complement  after  immunization  with  AChR  to 
determine  whether  expression  of the acute  phase  of EAMG  was  complement 
dependent. 
Materials and Methods 
AChR Preparation and Inoculation.  AChR was prepared from the electric organs of Electropho- 
rus  electricus  (11)  and  Torpedo  Californica  (12)  as  described  previously.  Female  Lewis  rats 
(obtained from Simonsen Laboratories, Gilroy, Calif.), aged approximately 10 wk, were inoculated 
on a  single occasion in multiple intradermal sites either with AChR (5-10 ~g) plus CFA and B. 
pertussis vaccine (2),  or with adjuvants only. 
Antibody Preparation  and Inoculation.  Immunoglobulins were prepared by 40% ammonium 
sulfate precipitation from sera of rats immunized 25-100 days earlier with AChR and adjuvants or 
adjuvants only (8).  1 ml vol containing 40-60 mg protein was injected into the exposed jugular 
vein under ether anesthesia. 
Cobra Venom Factor Preparation  and Inoculation.  Cobra Factor (CoF) was prepared from the 
venom of Naja naja siamensis,  assayed  in vitro for anti-complementary activity  as  described 
elsewhere  (13),  and treated with  c~-paradibromo acetophenone to inhibit phospholipase A2. 2 A 
loading  dose  of CoF  (325  U/Kg)  was  given  i.p.  in five  divided  doses over the  first  24 h.  For 
subsequent maintenance of C3 depression, 65 U/Kg was injected every 48 h. 
Clinical and Electrophysiological Assessments.  Rats were weighed daily and tested for muscle 
weakness  which  was  graded  on  a  scale  ranging from  +  for  weak  cry  and  grip  to  + + +  for 
moribund as described previously (6).  Electromyograms were performed as described previously, 
and rats lacking spontaneous decrements of muscle action potential with slow repetitive motor 
nerve stimulation were retested after i.p.  injection of 8  /~g curare  (14).  A  consistent decrement 
->10% (fifth response compared with first) was considered significant. 
Histology.  Frozen  sections  (8  ~m)  of forelimb  extensor  muscles  were  formalin  fixed  and 
stained with hematoxylin and eosin after histechemical reaction with a-naphthyl acetate to locate 
end plate cholinesterase (7). 
Quantitation  of Muscle AChR  and of AChR Complexed  in Situ with Antibody.  AChR was 
extracted with 2% Triton X-100 from washed pelleted membranes of homogenized individual rat 
carcasses (15).  An aliquot  of  each rat extract  was incubated overnight with 1251-a-bungarotexin 
(a-BT) to  label  AChR which was then  precipitated  by sequential  addition  of  excess  rat  anti-AChR 
antibodies  and goat anti-rat  Ig. AChR concentration  was expressed in terms  of  moles of  12~I-a-BT 
precipitated.  The proportion  of  AChR which  was  already complexed  with  antibody when extracted 
from muscle was determined from the cpm of  1251-a-BT  directly  precipitated  by goat anti-rat  Ig 
without addition  of  anti-AChR antibodies  (15). 
Antibody  Assays.  AChR  solubilized  from normal rat muscle and labeled with ~25I-a-BT 
provided antigen  for  testing  sera in an indirect  immunoprecipitation  assay (6, 15). 
C3 Assays.  Serum C3 was measured by the Mancini immunodiffusion technique. Anti-rat  C3 
antiserum was raised  by immunizing rabbits  i.d.  with  an incomplete Freund's adjuvant  emulsion 
containing repeatedly  washed precipitates  of  boiled  zymosan reacted  with  fresh  rat  serum. The Ig 
fraction  of  pooled rabbit  antisera  was absorbed with rat  Ig, and showed a single  precipitin  band 
when reacted  with  whole  normal rat  serum and  little  or  no  reaction  with  serum of  rats  depleted  of 
C3 with CoF. The precipitin  band was identified  as C3 in immunoelectrophoretic  analysis. 
Results 
C3 Values.  All experiments were completed within 5 days of commencing 
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TABLE  [ 
Effects of Complement Depletion  on the Outcome of Passively Transferred Anti-AChR 
Antibodies at Low and High Doses 
Ex-  Immunoglobulins  Treatment  Incidence of 
peri.  injected 
ment  Clinical  EMG  Inflam- 
num-  signs  Decre-  matory 
bor  ment  cells 
AChR  Extracted from muscle 
Moles (xl0-")  %  Corn- 
mean  ±  SE (n)  plexed 
with anti- 
body 
mean  ±  SE 
Anti-AChR  (2  x  Saline  3/7  6/7  6/6  2.95 ~  0.09 (6)*  19 ± 0.8 
10  -H mol) 
Anti-AChR  (2  x  CoF  0/4  0/4  0/4  4.36 -+ 0.16 (4)  18 ±  1.0 
10 " mol) 
Nil  Nil  0/5  -  0/3  4.08 -+ 0.21 (5)  0 
Anti-AChR (20  x  Saline  5/5  4/45  414  2.05 ±  0.21 (5)*  53 ±  3.0 
10  -H mol) 
Anti-AChR (20  x  CoF  0/5  0/5  0/5  3.56 ±  0.13 (6)  60 +- 2.0 
10  -'~  tool) 
Adjuvant  CoF  0/2  0/2  0/2  3.55, 4.25  0 
Nil  Nil  0/2  -  -  3.00, 3.16  0 
* Values for AChR  extracted from muesle of  antibody recipients treated with saline were significantly lower than controls (P < 
0.001, Student's t test). Values for antibody recipients treated with CoF did not differ from controls. 
One rat died before testing. The four survivors had + +/+ ÷ + weakness and spontaneous decrements of muscle action potential 
on repetitive motor nerve stimulation; rats in  all other groups were tested after challenge with curare,  and none showed  a 
decrement except the saline-treated recipients of the lower dose  of antibodies. 
CoF and the mean serum C3 value of  rats treated with CoF (48 h earlier)  was 
11% of  that in rats treated with saline. 
Effects  of Passively  Transferred Anti-AChR  Antibodies.  Two separate  ex- 
periments  were  performed  by  employing  syngeneic  Ig  preparations  which 
differed 10-fold in their content of antibodies to muscle AChR (2 and 20 x  10-" 
mol per ml,  respectively).  This  allowed comparison  of the effects of antibody 
doses less than and in excess of the total amount of AChR extractable from an 
average rat's musculature  (3-5  ×  10-" moles). CoF (or saline) was commenced 
2 days before Ig injection and rats were killed by ether inhalation 3 days after Ig 
injection, immediately after electromyogram (EMG) tests. 
Rats treated with saline, i.e. having normal C3 levels, developed clinical and 
electrophysiological  signs  of EAMG  after  injection  of anti-AChR  antibodies 
(Table I). The smaller dose of antibodies (2 ×  10 -11 moles) used in experiment I 
induced  mild  clinical  signs  (+),  without a  spontaneous EMG decrement,  but 
enhanced  curare  sensitivity  was  demonstrated  electromyographically.  There 
was a  32% reduction in  muscle AChR.  In experiment  II,  rats  injected with  a 
larger dose of antibodies  (20  ×  10 -'~  moles) had clinically more severe EAMG 
(++/+++)  with profound  weight loss  (Fig.  1),  and  spontaneous  EMG decre- 
ments;  muscle AChR was 41%  less than  that  of control groups which did not 
receive anti-AChR  antibodies.  Inflammatory  cells, predominantly  mononucle- 
ated,  were found in the  motor end plate  regions of muscle from recipients  of 
both high and low doses of antibodies.  The inflammatory cells were intimately 
associated with cholinesterase-positive  material  (i.e.  pestsynaptic membrane) 
which, in many instances,  was sequestered away from the muscle fiber and in a 
granular,  disintegrated form (Fig.  2). 
Injection of anti-AChR antibodies into rats depleted of C3 by CoF treatment, 
induced  neither  weakness,  significant  weight  loss  (Fig.  1),  a  decrementing 976  COMPLEMENT IN  EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS 
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FIG.  I.  Mean weight changes (_+ SD) of  two groups of  five  rats  injected  on day 0 with 20 
x  10  -I' tool  anti-rat  muscle AChR  antibodies (mean starting  weight =  195 _+ 12 g). The 
group treated with CoF had  neither clinical  signs  of weakness,  nor enhanced  curare 
sensitivity;  the group treated with saline had + +/+  ÷ +  EAMG  and spontaneous decre- 
ments  of muscle  action potential when  tested by  EMG  with  repetitive motor  nerve 
stimulation. 
FIG. 2.  Motor end  plate  region of  digit  extensor muscle from  a  rat  72  h aider  being  treated 
with saline and injected  i.v.  with anti-AChR  antibodies. Numerous  inflammatory cells 
surround three areas of  darkly  stained cholinesterase  reaction  products (arrows)  which are 
sequestered from muscle fibers.  Granular appearance is  particularly  evident in  the  area  on 
the right  (Fig.  3). (hematoxylin and eosin, x 400). 
response  to  repetitive  nerve  stimulation,  nor  an  increased  curare  sensitivity 
(Table  I).  The amount  of AChR  solubilized from muscle did not differ signifi- 
cantly  from  that  of  control  rats  not  injected  with  anti-AChR  antibodies. 
However,  AChR  extracted  from  rats  treated  with  CoF  was  found  to  have LENNON~  SEYBOLD~  LINDSTROM,  COCHRANE~  AND  ULEVITCH  977 
FIG.  3.  Motor end  plate  region of digit  extensor muscle  from  a  rat  72  h  after being 
decomplemented with  CoF  and  injected i.v.  with  anti-AChR antibodies.  Two  areas  of 
darkly stained cholinesterase reaction products (arrows) are seen from above and from the 
side. They are compact, have a normal appearance, and can be demonstrated to be closely 
applied to the muscle fibers. No inflammatory cells are seen.  (hematoxylin and eosin,  × 
400). 
antibody  bound to it,  and,  indeed,  the  absolute amount  of AChR complexed 
with antibody was greatest in C3-depleted rats injected with the larger dose of 
antibodies (Table I). Motor end plate regions (Fig. 3) lacked inflammatory cells, 
and  the  cholinesterase  reaction  products  resembled those of normal  rats  and 
rats injected with adjuvant Ig alone. 
Evidence for Complemenf  s Role in Destruction of the Postsynaptic Membrane 
in the Acute Phase of EAMG Induced by Immunization  with AChR.  C3 has 
been  reported  to  play  a  role  in  the  induction  of immune  responses  to  T- 
dependent  antigens  (16).  Thus,  to  ascertain  whether  our  protocol  for  CoF 
administration  might  inhibit  induction  of T-cell  responses  in  Lewis  rats,  a 
preliminary  experiment  was performed in another model disease-hyperacute 
experimental autoimmune encephalomyelitis (HEAE). HEAE induced in Lewis 
rats  by guinea  pig  myelin  basic  protein  has  the  same  time-course  as  acute 
EAMG  (17)  but immunopathologic  lesions appear  to be mediated entirely by 
effector T cells. Injection of CoF from the 7th day after inoculation with 30 ~g 
guinea pig myelin basic protein plus CFA and B. pertussis caused depletion of 
serum C3, but did not delay the onset or inhibit the severity of HEAE. 
To investigate  whether complement  may have an  effector role in the acute 
phase  of EAMG  induced  by  active  immunization,  CoF  treatment  was  com- 
menced  on  the  7th  day  after  inoculation  with  Torpedo  AChR.  Of  18  rats 
inoculated with AChR and adjuvants,  6 received CoF,  and  12 received saline. 
When  sacrificed  on  the  l lth  postinoculation  day  (the  expected  time  of peak 
incidence  of acute EAMG),  serum  titers  of antibody to Torpedo AChR in the 978  COMPLEMENT  IN  EXPERIMENTAL  AUTOIMMUNE  MYASTHENIA  GRAVIS 
TABLE  II 
Effect of CoF on the Acute Phase of EAMG Induced by Active Immunization with 
Torpedo AChR 
Incidence of  AChR Extracted from muscle 
% Complexed 
Immu-  Treatment  Clini-  EMG  In-  Range  with antibody 
nogen  cal  Dec-  flam-  (moles x 
signs  re-  matory 
ment  cells  10-H)  Mean  Range 
AChR  Saline  8/12  8/11"  7/10  3.2 --, 8.55  3.2  (1-6) 
AChR  CoF  1/6  0/6  0/4  5.1 --~ 5.4  1.0  (0-2) 
Adjuvant  CoF  0/5  0/5  0/3  5.0 --* 5.6  0  - 
* Six rats  had spontaneous decrements of muscle action  potential  on repetitive  motor nerve 
stimulation, and two more in this  group, but none in the other groups, showed a decrement 
after  challenge with curare. 
5 A wide range of  values for  muscle AChR is  characteristic  of  acute EAMG  (see  text). 
group treated with CoF (mean _  SD =  1.99 _  0.85  x  10 -7 M, n  = 4) were in the 
lower range oftiters of the group treated with saline (3.65 _+ 1.38, n  =  11). This 
difference  (P  -  0.05,  Wilcoxon's  rank  test)  suggests  that  injection  of CoF 
slightly depressed  the  humoral immune response  to  AChR,  which  requires 
participation of helper T cells (2, 4).  One rat treated with CoF developed mild 
weakness  on  day  9  but  none  had  EMG  evidence  (curare  test)  of impaired 
neuromuscular transmission. 8 of 12 rats treated with saline developed weak- 
ness  ranging  from  +  to  +++  severity,  and  EMG  evidence  of  impaired 
neuromuscular transmission (Table II). Three of  the eight rats with clinical and 
electrophysiological signs of acute EAMG had antibody titers in the same range 
as rats treated with CoF. 
The amount of  AChR extracted from the musculature of rats inoculated with 
AChR and treated with CoF  (5.1-5.4  x  10 -~1  mol) did not differ significantly 
from that of controls inoculated with adjuvants (5.0-5.6  x  10 -H mol), whereas 
values in rats inoculated with AChR and treated with saline varied over a wide 
range (3.2-8.5  x  10 -H tool). A wide range of muscle AChR content is character- 
istic of acute EAMG (15), and presumably reflects variable loss and resynthesis 
of AChR. In both saline and CoF-treated groups, only a  small amount of the 
extracted AChR had antibody bound to it. This also is characteristic of  the acute 
phase of EAMG in normal rats (15). 
In 7 of 10 muscle biopsies available from the saline-treated group, mononu- 
clear cells were abundant and in intimate association with granular cholines- 
terase-positive material. The cholinesterase-positive material (i.e. postsynaptic 
membrane) was frequently detached from muscle fibers. The motor end plate 
regions of four rats examined after CoF treatment (including the one with mild 
weakness) resembled those of control rats inoculated with adjuvants only: the 
cholinesterase-positive material  was  compact  and  closely applied  to  muscle 
fibers with no evidence of inflammatory cells. 
Discussion 
The present study has established that complement plays a  critical role in 
vivo  in  mediating impairment  of neuromuscular transmission  in  the  acute LENNON,  SEYBOLD,  LINDSTROM,  COCHRANE,  AND  ULEVITCH  979 
phase of EAMG induced either by passive transfer of anti-AChR antibodies or 
by active immunization with AChR. Injection of syngeneic anti-AChR antibod- 
ies in excess of the muscle's content of AChR was without any measurable effect 
in rats treated with CoF. There was no weakness or impairment  of neuromus- 
cular transmission  as judged electromyographically by curare sensitivity,  and 
the absolute amount of AChR was uniformly within the normal range despite 
complexing of 60% of AChR with antibody. 
Had binding of antibodies to the postsynaptic membrane induced redistribu- 
tion (4,  12) and accelerated degradation  of surface AChR (18-21), as have been 
reported in vitro from studies with both rat and human anti-AChR antibodies 
on extrajunctional AChR of cultured muscle cells, one might expect an increase 
in curare sensitivity and also some alteration (either a decrease, or increase, by 
72 h) in the amount of AChR extractable from muscle. Thus if antibody-induced 
modulation of AChR does occur in the intact adult neuromuscular junction, that 
mechanism does not appear to contribute significantly to the reduction of ACh 
sensitivity of the postsynaptic membrane induced in vivo by passive transfer of 
anti-AChR antibodies. 
Impairment  of the ionophore function of AChR by antibodies has also been 
suggested  from  in  vitro  studies  as  a  mechanism  by which  antibodies  might 
impair neuromuscular transmission.  Again one might anticipate an increase in 
curare  sensitivity,  if this  mechanism  were  a  significant  pathogenic  factor. 
However, since neuromuscular transmission in the rat has such a  large "safety 
factor", these apparently minor mechanisms of impairing neuromuscular trans- 
mission could be of importance in membranes whose content of AChR has been 
greatly reduced by complement-dependent mechanisms. 
Observations by Toyka et al.  (22) in  mice injected with IgG from patients 
with MG, suggested that components of the complement system activated early 
in the  cascade  were important  mediators  of neuromuscular  transmission  im- 
pairment  by anti-AChR  antibodies  in  vivo.  They  found  that  recipient  mice 
treated with CoF developed less severe signs of MG (reduction of miniature end 
plate potential  [MEPP] amplitude and decreased a-BT binding sites in muscle) 
than did normal recipient mice. In contrast, recipient mice genetically deficient 
in  C5  were  affected  as  severely by  MG  immunoglobulins  as  normals.  This 
implied that lytic components of complement were not involved in impairment 
of neuromuscular transmission by antibodies and complement. 
The present study has provided evidence for a complement-dependent mech- 
anism  of membrane  destruction  which need  not require the  terminal  compo- 
nents of complement. Activation of complement by antibodies binding to AChR 
in the postsynaptic membrane  appears to provide a  signal  that  is directly or 
indirectly chemotactic for mononuclear inflammatory cells. Inflammatory cells 
did  not  accumulate  in  the  motor  end  plates  of rats  depleted  of complement 
either  before passive transfer  of anti-AChR  antibodies  or 7 days after active 
immunization with AChR. A destructive mononuclear cellular response, which 
is  similarly  both  transferable  by antibodies  and  complement-dependent,  has 
been described in a  guinea pig model of experimental  autoimmunity  to renal 
tubular  basement  membranes  (23). Electron  microscopy  has  revealed  that 
destruction of the postsynaptic membrane in acute EAMG is effected principally 
by cells resembling macrophages  (7). Nonimmune lymphoid cells which attack 980  COMPLEMENT  IN  EXPERIMENTAL  AUTOIMMUNE  MYASTHENIA  GRAVIS 
the postsynaptic membrane presumably bear receptors for Ca and the Fc piece 
of IgG complexed with antigen. We previously reported that anti-AChR antibod- 
ies detectable in the serum of rats with EAMG (day 10) were predominantly 7S 
(2).  It  has  been  demonstrated  in  the  rabbit  that  homologous  anti-AChR 
antibodies are cytophilic for macrophages (24). C3 receptors on lymphoid cells 
have been proposed to play a role in vivo in promoting antibody-dependent cell- 
mediated cytotoxicity (ADCC), which is inhibited in vitro by concentrations of 
IgG which exist in vivo (25). Furthermore, Fc receptors on lymphoid cells have 
been reported to bind inefficiently to particle bound Fc (16). Thus IgG and C3 
probably  act  synergistically in  opsonization  and phagocytosis of particulate 
antigens. The binding of a macrophage's C3 receptors to the activated form of C3 
on  the  postsynaptic  membrane  would  promote  interaction  between  its  Fc 
receptors and IgG on the postsynaptic membrane, thus triggering phagocytosis. 
If this picture of acute EAMG is correct, then the absence of inflammatory 
cells at the motor end plate in chronic EAMG must be explained. First,  it is 
possible  that after initial destruction of the postsynaptic membrane by comple- 
ment-dependent mechanisms, immune complexes (AChR, IgG, and C3) on the 
remaining membrane are no longer of sufficient number or in optimal array for 
effective interaction with lymphoid cells bearing Ca and Fc receptors, and no 
longer give rise to an adequate chemotactic signal for inflammatory cells.  This 
hypothesis would  most readily explain  the abrupt termination of the  acute 
phase of EAMG. Pronounced clinical recovery from acute EAMG, which is often 
observed over the course of 8 h (V. Lennon, unpublished observation), probably 
reflects  return  of the  nerve  terminals  into  proximity  to  remnants  of the 
postsynaptic membrane after disappearance of inflammatory cells.  A  second 
possible explanation for termination of acute EAMG is that Fc and C3 receptors 
on  effector lymphoid cells  might  become  occupied  by  soluble  complexes of 
antigen  and  antibody  appearing  in  the  circulation with  progression  of the 
immune response induced by inoculation with AChR and adjuvants.  Because 
the ratio of antigen and antibody is critical for effecting ADCC in vitro (26), a 
third possibility is that the transient increase in muscle AChR which follows 
separation of nerve terminals from postsynaptic membranes by inflammatory 
cells (15), might inhibit lymphoid cells from binding to postsynaptic immune 
complexes. In MG,  a  possible  explanation for rarity of inflammatory cells at 
neuromuscular junctions could be that the Fc piece of the IgG subclass(es) of 
human anti-AChR antibodies may not be cytophilic for lymphoid cells. 
Deposition of homologous Ca has been demonstrated by indirect immunofluo- 
rescence on the membranes of cultured muscle cells exposed to anti-AChR anti- 
bodies  from rats  with  acute or chronic EAMG  (4). Although cultured myo- 
tubes  were  not  lysed  after  binding  homologous  antibody  and  complement 
(4),  complement-mediated lysis  may occur in  vivo  in  the  highly specialized 
postsynaptic membrane. Engel and co-workers have demonstrated focal lysis of 
the tips of postsynaptic membrane folds  electron microscopically in  MG  (27), 
and  in  chronic  EAMG,  and  also  early  in  acute  EAMG  in  the  absence  of 
inflammatory cells (7). Immunoelectron microscopic  studies of the neuromus- 
cular junction in both chronic EAMG (28) and MG (27) suggest that lysis of the 
postsynaptic membrane is complement-mediated-both IgG and C3 were dem- 
onstrated on degenerating membrane fragments in the synaptic cleft. C3 was LENNON,  SEYBOLD, LINDSTROM, COCHRANE,  AND  ULEVITCH  981 
demonstrated  also on the postsynaptic membrane in the same distribution as 
bound IgG (27) and residual AChR (i.e.  a-BT binding sites) (9). In mild cases of 
MG,  where  ultrastructural  abnormality  of the  postsynaptic  membrane  and 
reduction of AChR were minimal, a maximal area of membrane was covered by 
IgG and C8, but reduction  in MEPP amplitude was at most only 40%  (27).  In 
more clinically severe cases of MG, MEPP amplitude reduction was paralleled 
by reduction in AChR, IgG, and C3 on the postsynaptic membrane.  It could be 
concluded from those studies that  in severe cases of MG the mere presence of 
IgG  and  C3  on  the  postsynaptic  membrane  was  not  the  major  cause  of the 
marked reduction in MEPP amplitude; membrane destruction and accompany- 
ing loss of AChR (29) were more important. 
The present study in decomplemented rats has provided direct evidence that 
binding  of antibody to AChR at the neuromuscular junction  does not signifi- 
cantly  compromise  neuromuscular  transmission  unless  the  amount  of AChR 
also is reduced.  Complement appears to play a  central role in vivo, at least in 
the  acute  phase  of  EAMG  in  rats,  in  mediating  both  destruction  of  the 
postsynaptic membrane and loss of AChR which is initiated by the binding of 
anti-AChR antibodies. 
Summary 
An  acute  phase  of experimental  autoimmune  myasthenia  gravis  (EAMG) 
occurs  transiently  early  in  the  immune  response  of Lewis  rats  to  nicotinic 
acetylcholine receptors (AChR) when Bordetella pertussis is used as adjuvant. 
It is characterized by a  destructive cellular attack directed at the postsynaptic 
membrane of muscle. Acute EAMG can be passively transferred to normal rats 
by IgG from  serum  of rats  with  chronic  EAMG.  In the present  study,  acute 
EAMG, induced either by passive transfer of syngeneic antibodies or by active 
immunization,  was inhibited in rats depleted of complement by treatment with 
cobra venom factor (CoF). Furthermore,  passive transfer of antibodies in excess 
of the  muscle's  content  of AChR was  without  any  measurable  effect in  rats 
treated  with  CoF.  Although  60%  of the  muscle's  AChR was  complexed  with 
antibody,  there  was  no  reduction  in  the  muscle's  content  of  AChR,  and 
neuromuscular transmission  was not compromised as judged electromyograph- 
ically by curare sensitivity.  These data imply that redistribution,  accelerated 
degradation,  and  impairment  of the  ionophore  function  of AChR,  effects of 
antibodies described in vitro on extrajunctional AChR, do not play a significant 
role in vivo in impairing  neuromuscular transmission  in an intact  neuromus- 
cular junction.  Complement  appears  to  be a  critical  mediator  of anti-AChR 
antibodies' pathogenicity in vivo. 
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